Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTHFD1 | P11586 | 2/20 | 0.86 |
| ▸ | DHFR | P00374 | 1/20 | 0.81 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.69 |
| ▸ | MTHFD2 | P13995 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | FPGS | Q05932 | 2/20 | 0.61 |
| ▸ | TYMS | P04818 | 1/20 | 0.58 |
| ▸ | ATIC | P31939 | 3/20 | 0.57 |
| ▸ | GART | P22102 | 6/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levomefolic Acid SCHEMBL30051011 | 1.00 | MTHFD1 (0.86) | MTHFD1DHFRSOSTMTHFD2LMNA | |
| Levomefolic Acid SCHEMBL29422840 | 1.00 | MTHFD1 (0.86) | MTHFD1DHFRSOSTMTHFD2LMNA | |
| Levomefolic Acid SCHEMBL31173596 | 1.00 | MTHFD1 (0.86) | MTHFD1DHFRSOSTMTHFD2LMNA | |
| Levomefolic Acid SCHEMBL7678398 | 1.00 | MTHFD1 (0.86) | MTHFD1DHFRSOSTMTHFD2LMNA | |
| Levomefolic Acid SCHEMBL79039 | 1.00 | MTHFD1 (0.86) | MTHFD1DHFRSOSTMTHFD2LMNA | |
| Levomefolic Acid SCHEMBL29616390 | 1.00 | MTHFD1 (0.86) | MTHFD1DHFRSOSTMTHFD2LMNA | |
| Levomefolic Acid SCHEMBL258787 | 1.00 | MTHFD1 (0.86) | MTHFD1DHFRSOSTMTHFD2LMNA | |
| Levomefolic Acid SCHEMBL1882912 | 1.00 | MTHFD1 (0.86) | MTHFD1DHFRSOSTMTHFD2LMNA | |
| Levomefolic Acid SCHEMBL4727836 | 1.00 | MTHFD1 (0.86) | MTHFD1DHFRSOSTMTHFD2LMNA | |
| Levomefolic Acid SCHEMBL30828726 | 1.00 | MTHFD1 (0.86) | MTHFD1DHFRSOSTMTHFD2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220279831-A1 | COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATION | EXELTIS FRANCE (FR) | 2022-09-08 | — | — | US | claimed |
| US-20170202802-A1 | COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATION | EXELTIS USA, INC. | 2017-07-20 | — | — | US | claimed |
| US-20170112178-A1 | COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATION | Chemo S.A. France (FR) | 2017-04-27 | — | — | US | claimed |
| US-20130011377-A1 | COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATION | Chemo S.A. France (FR) | 2013-01-10 | — | — | US | claimed |
| US-20220279831-A1 | COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATION | EXELTIS FRANCE (FR) | 2022-09-08 | — | — | US | disclosed |
| US-20220079201-A1 | COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATION | EXELTIS FRANCE (FR) | 2022-03-17 | — | — | US | disclosed |
| US-20170202802-A1 | COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATION | EXELTIS USA, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170112178-A1 | COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATION | Chemo S.A. France (FR) | 2017-04-27 | — | — | US | disclosed |
| US-20140023751-A1 | COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATION | Chemo S.A. France (FR) | 2014-01-23 | — | — | US | disclosed |
| US-8545896-B2 | Compositions, kits and methods for nutrition supplementation | Chemo S. A. France (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20130084344-A1 | COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATION | Chemo S.A. France (FR) | 2013-04-04 | — | — | US | disclosed |
| US-20130011377-A1 | COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATION | Chemo S.A. France (FR) | 2013-01-10 | — | — | US | disclosed |
| US-8183227-B1 | Compositions, kits and methods for nutrition supplementation | Chemo S. A. France (FR) | 2012-05-22 | — | — | US | disclosed |
| US-8168611-B1 | Compositions, kits and methods for nutrition supplementation | Chemo S.A. France (FR) | 2012-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130084344-A1 | COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATION | FADS1, FADS2, VDR | MTHFD1 1459/4885DHFR 1710/4885SOST 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.